Use of lp82 to treat hematopoietic disorders
CA 2433933 A1 · Owner: Noblitt, Timothy Wayne · Inventors: Noblitt, Timothy Wayne; Heuer, Josef Georg; Liu, Ling
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist LP82 antagonist, LP82 , polynucleotide LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders including, but not , limited to, anemia leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 14, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 14, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 14, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.